News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with Teva Pharmaceutical Industries Limited (TEVA)'s COPAXONE(R)


10/11/2011 11:58:47 AM

JERUSALEM, Israel--(BUSINESS WIRE)--Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE® (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies (DMTs).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES